Can patients with advanced lung cancer take crizotinib?

Patients with advanced lung cancer can take crizotinib (Crizotinib), especially for ALK fusion gene-positive non-small cell lung cancer (NSCLC) and ROS1 fusion gene-positive NSCLC patients. Crizotinib is a targeted drug targeting ALK and ROS1 protein kinases. It blocks the proliferation and growth of tumor cells by inhibiting the activity of these protein kinases. Crizotinib has been approved for first-line and second-line treatment of patients with advanced lung cancer who are positive for the ALK and ROS1 fusion genes. In first-line treatment, crizotinib is often used as the drug of choice and can significantly prolong patients' progression survival (PFS). In second-line therapy, crizotinib is also an effective treatment option for patients who have progressed or developed resistance to other treatment options. Please follow your doctor’s treatment plan for details.